Compensation norms create inequity in clinical trials.
Imagine a patient participating in a clinical trial for a new vaccine. They take a half day of PTO to visit the clinic, which is a short 15-minute drive from their home. After an hour visit, they are given $50 as compensation – a reasonable amount which they spend on a nice dinner. This describes […]
SubjectWell Raises $35 Million to Expand Patient Access to New Treatment Options
AUSTIN, TX, October 18, 2022 – SubjectWell, the largest engagement platform for matching patients with chronic health conditions to new care options, today announced a $35 million Series B funding round led by Asset Management Ventures, with participation from all existing investors, and joined by Bertelsmann. This new investment will accelerate the growth of SubjectWell’s […]
Accommodations Increase Clinical Trial Participation for Patients of Color, Survey Reveals
Bilingual staff boost Spanish speaker interest in trials: study
Spanish-speaking patients show strong interest in clinical trial participation in the US.
For a clinical trial to be successful, patients need to be the top priority. However, language barriers faced during the clinical trial process can often result in lower participation rates of non-English speakers, an unsatisfactory patient experience and, ultimately, imprecise data. In the US, the leading country in clinical trial participation each year, language barriers […]
Patient attitudes toward clinical research continue to evolve during the COVID-19 pandemic.
At SubjectWell, we have been conducting an ongoing survey since the beginning of the pandemic to understand how patient attitudes toward clinical research participation have been affected. As the coronavirus pandemic continues, we continue to see how the rapidly evolving situation is also changing the clinical trial landscape. The third round of our survey was […]
SubjectWell expands trial recruitment marketplace to oncology indications
Non-small cell lung cancer patients show strong interest in clinical trial participation across disease progression.
In February 2022, SubjectWell announced the expansion of its proven marketplace to include oncology clinical trials, beginning with non-small cell lung cancer (NSCLC). Lung cancer is by far the leading cause of cancer death, and more specifically, the vast majority of lung cancer diagnoses are NSCLC. To develop a better understanding of NSCLC patients’ attitudes […]
SubjectWell Announces Marketplace Expansion into Oncology Clinical Trials
AUSTIN, TX, March 16, 2022 – SubjectWell, the risk-free clinical trials marketplace for patient recruitment, announced today it has expanded its services to include oncology clinical trials, beginning with non-small cell lung cancer (NSCLC). The company is leveraging its proven clinical trial marketplace, which has been used to reach patients across more than 175 therapeutic […]
